Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Price, Quote, News and Overview

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

52.67  -1.32 (-2.44%)

EXAS Quote, Performance and Key Statistics

EXACT SCIENCES CORP

NASDAQ:EXAS (5/7/2025, 12:30:08 PM)

52.67

-1.32 (-2.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High72.83
52 Week Low39.97
Market Cap9.93B
Shares188.59M
Float186.23M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE103.85
Earnings (Next)07-29 2025-07-29/amc
IPO01-30 2001-01-30


EXAS short term performance overview.The bars show the price performance of EXAS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20

EXAS long term performance overview.The bars show the price performance of EXAS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30

The current stock price of EXAS is 52.67 USD. In the past month the price increased by 23.18%. In the past year, price increased by 0.9%.

EXACT SCIENCES CORP / EXAS Daily stock chart

EXAS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.38 333.98B
AMGN AMGEN INC 13.19 147.26B
GILD GILEAD SCIENCES INC 12.81 123.40B
VRTX VERTEX PHARMACEUTICALS INC N/A 112.09B
REGN REGENERON PHARMACEUTICALS 12.73 60.92B
ARGX ARGENX SE - ADR 328.03 38.06B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.82B
ONC BEIGENE LTD-ADR N/A 25.21B
BNTX BIONTECH SE-ADR N/A 22.71B
NTRA NATERA INC N/A 21.44B
SMMT SUMMIT THERAPEUTICS INC N/A 17.90B
BIIB BIOGEN INC 7.41 17.17B

About EXAS

Company Profile

EXAS logo image EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Company Info

EXACT SCIENCES CORP

5505 Endeavor Lane

Madison WISCONSIN 53719 US

CEO: Kevin T. Conroy

Employees: 6900

EXAS Company Website

EXAS Investor Relations

Phone: 16082845700

EXACT SCIENCES CORP / EXAS FAQ

What is the stock price of EXACT SCIENCES CORP today?

The current stock price of EXAS is 52.67 USD. The price decreased by -2.44% in the last trading session.


What is the ticker symbol for EXACT SCIENCES CORP stock?

The exchange symbol of EXACT SCIENCES CORP is EXAS and it is listed on the Nasdaq exchange.


On which exchange is EXAS stock listed?

EXAS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EXACT SCIENCES CORP stock?

34 analysts have analysed EXAS and the average price target is 70.68 USD. This implies a price increase of 34.19% is expected in the next year compared to the current price of 52.67. Check the EXACT SCIENCES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EXACT SCIENCES CORP worth?

EXACT SCIENCES CORP (EXAS) has a market capitalization of 9.93B USD. This makes EXAS a Mid Cap stock.


How many employees does EXACT SCIENCES CORP have?

EXACT SCIENCES CORP (EXAS) currently has 6900 employees.


What are the support and resistance levels for EXACT SCIENCES CORP (EXAS) stock?

EXACT SCIENCES CORP (EXAS) has a support level at 43.76 and a resistance level at 54. Check the full technical report for a detailed analysis of EXAS support and resistance levels.


Is EXACT SCIENCES CORP (EXAS) expected to grow?

The Revenue of EXACT SCIENCES CORP (EXAS) is expected to grow by 11.21% in the next year. Check the estimates tab for more information on the EXAS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EXACT SCIENCES CORP (EXAS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EXACT SCIENCES CORP (EXAS) stock pay dividends?

EXAS does not pay a dividend.


When does EXACT SCIENCES CORP (EXAS) report earnings?

EXACT SCIENCES CORP (EXAS) will report earnings on 2025-07-29, after the market close.


What is the Price/Earnings (PE) ratio of EXACT SCIENCES CORP (EXAS)?

EXACT SCIENCES CORP (EXAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.18).


What is the Short Interest ratio of EXACT SCIENCES CORP (EXAS) stock?

The outstanding short interest for EXACT SCIENCES CORP (EXAS) is 5.86% of its float. Check the ownership tab for more information on the EXAS short interest.


EXAS Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to EXAS. When comparing the yearly performance of all stocks, EXAS turns out to be only a medium performer in the overall market: it outperformed 65.86% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EXAS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to EXAS. The financial health of EXAS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EXAS Financial Highlights

Over the last trailing twelve months EXAS reported a non-GAAP Earnings per Share(EPS) of -5.18. The EPS decreased by -292.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -17.86%
ROE -42.55%
Debt/Equity 0.97
Chartmill High Growth Momentum
EPS Q2Q%65%
Sales Q2Q%10.86%
EPS 1Y (TTM)-292.42%
Revenue 1Y (TTM)11.57%

EXAS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to EXAS. The Buy consensus is the average rating of analysts ratings from 34 analysts.

For the next year, analysts expect an EPS growth of 91.39% and a revenue growth 11.21% for EXAS


Ownership
Inst Owners100.85%
Ins Owners0.99%
Short Float %5.86%
Short Ratio4.3
Analysts
Analysts85.29
Price Target70.68 (34.19%)
EPS Next Y91.39%
Revenue Next Year11.21%